Who is sponsoring NCT05065801?

NCT05065801 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle.

What drugs are being tested in NCT05065801?

Interventions in NCT05065801: GEMBRAX/FOLFIRINOX Arm A, FOLFIRINOX Arm B.

What condition does NCT05065801 study?

NCT05065801 studies Metastatic Pancreatic Cancer.

Is NCT05065801 still recruiting?

NCT05065801 is currently recruiting now. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT05065801: GABRINOX2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients

Recruiting now Phase 2 Last updated 15 April 2026

What this trial tests

Phase 2 trial testing GEMBRAX/FOLFIRINOX Arm A in Metastatic Pancreatic Cancer in 162 participants. Currently enrolling.

Timeline

11 January 2022

Primary endpoint
30 December 2026

30 June 2028

Quick facts

Lead sponsor	Institut du Cancer de Montpellier - Val d'Aurelle
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	162
Start date	11 January 2022
Primary completion	30 December 2026
Estimated completion	30 June 2028
Sites	8 locations across France

Drugs / interventions tested

GEMBRAX/FOLFIRINOX Arm A
FOLFIRINOX Arm B

Conditions studied

Metastatic Pancreatic Cancer — all drugs for Metastatic Pancreatic Cancer →

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle — full company profile →

Who can join

Adults 18 to 75, any sex, with Metastatic Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the efficacy of sequential treatment (Gabrinox) comprising Gembrax regimen (Gemcitabine -Abraxane) followed by the Folfirinox regimen (5FU, Oxaliplatin and Irinotecan) compared to folfirinox alone in patients treated in first metastatic line pancreatic cancer

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Chemotherapy and radiotherapy for advanced pancreatic cancer.
Haggstrom L, Chan WY, Nagrial A, Chantrill LA, et al · · 2024 · cited 12× · PMID 39635901 · DOI 10.1002/14651858.cd011044.pub3
The road to overcome pancreatic cancer: Where are we?
Tirpe A, Streianu C, Isachesku E, Simon I, et al · · 2024 · cited 6× · PMID 39403527 · DOI 10.1016/j.heliyon.2024.e38196
Trend of albumin nanoparticles in oncology: a bibliometric analysis of research progress and prospects.
Liu Y, Li Y, Shen W, Li M, et al · · 2024 · cited 6× · PMID 39070787 · DOI 10.3389/fphar.2024.1409163
GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer.
Portales F, Gourgou S, Fiess C, Salasc F, et al · · 2025 · PMID 40819868 · DOI 10.1136/bmjopen-2025-104228

Verify or expand the search:

Other recruiting trials for Metastatic Pancreatic Cancer

Currently open trials in the same condition.

NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT06843551 — The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation · Phase 2 · recruiting
NCT06951997 — QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer · Phase 2 · recruiting
NCT06533332 — A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors · Phase 1 · recruiting

Other Institut du Cancer de Montpellier - Val d'Aurelle trials

Trials by the same sponsor.

NCT07523152 — Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With H · NA · not yet recruiting
NCT07198971 — Feasibility Study Incorporating Music Therapy to Optimise the Smoking Cessation Process Coordinated by a Tobacco Addicti · NA · recruiting
NCT07043543 — Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11) · NA · not yet recruiting
NCT07441941 — Single-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life Workup · recruiting
NCT06382818 — Personalization of Breast Radiotherapy According to Loco-regional Recurrence Risk and Toxicity Probability · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05065801 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut du Cancer de Montpellier - Val d'Aurelle
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05065801.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing